

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number
WO 2006/013106 A3

(51) International Patent Classification:

C12N 15/49 (2006.01) A61K 39/295 (2006.01)
C07K 14/16 (2006.01) C12N 15/62 (2006.01)
A61K 39/21 (2006.01)

(21) International Application Number:

PCT/EP2005/008434

(22) International Filing Date: 3 August 2005 (03.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0417494.2 5 August 2004 (05.08.2004) GB

(71) Applicant (for all designated States except US): **GLAXO-SMITHKLINE BIOLOGICALS SA** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ABRECHT, Helge** [DE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE). **DELCHAMBRE, Martine** [BE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE). **MARCHAND, Martine** [BE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE). **MATHY, Nathalie, Louise** [BE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE). **PERMANNE, Philippe, Jean, Gervais, Ghislain** [BE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE). **VOSS, Gerald, Hermann** [DE/BE]; GlaxoSmithKline Biologicals sa, rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **DALTON, Marcus, Jonathan, William**; Glaxo-SmithKline, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report

(88) Date of publication of the international search report:

17 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINE FOR PREVENTION AND TREATMENT OF HIV-INFECTION

(57) Abstract: This invention relates to HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof.



WO 2006/013106 A3